08:45 AM EDT, 08/13/2024 (MT Newswires) -- Apollomics ( APLM ) shares were soaring more than 116% in recent pre-bell activity Tuesday as the company reported "positive preliminary clinical data" from a phase 2 trial of vebreltinib, which is intended to treat patients non-central nervous system solid tumors.

The biopharmaceutical company said clinical data from a cohort in the trial showed a 43% objective response rate, a median overall survival of 12.4 months and a median progression-free survival of 4.5 months. It also said that the longest duration of response has been 18 months, with patients currently continuing treatment.

"The results in this specific cohort of patients adds to the accumulating evidence supporting the potential of vebreltinib as a highly selective and efficacious treatment against multiple tumor types harboring MET alterations," Chairman and Chief Executive Guo-Liang Yu said in a statement.

Price: 0.3428, Change: +0.18, Percent Change: +116.55